CompletedPhase 2NCT00023621
Celecoxib in Preventing Basal Cell Carcinoma in Patients With Basal Cell Nevus Syndrome
Studying Gorlin syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of California, San Francisco
- Principal Investigator
- Ervin Epstein, MDUniversity of California, San Francisco
- Intervention
- celecoxib(drug)
- Enrollment
- 60 target
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2001 – 2007
Study locations (2)
- UCSF Comprehensive Cancer Center, San Francisco, California, United States
- Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, New York, New York, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00023621 on ClinicalTrials.govOther trials for Gorlin syndrome
Additional recruiting or active studies for the same condition.